NASDAQ:BFRA Biofrontera (BFRA) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free BFRA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.51▼$2.7850-Day Range$2.50▼$3.6052-Week Range$2.09▼$7.54Volume7,263 shsAverage Volume27,512 shsMarket Capitalization$73.73 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Biofrontera alerts: Email Address Ad Insider FinancialThousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage" About Biofrontera Stock (NASDAQ:BFRA)Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.Read More Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! BFRA Stock News HeadlinesApril 4, 2024 | msn.comLeverkusener Pharma-AG: Warum Biofrontera sich weiter von seinem Gründer absetztApril 4, 2024 | finanznachrichten.deBiofrontera plant eine FinanzierungsrundeApril 23, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…March 19, 2024 | finance.yahoo.comQ4 2023 Biofrontera Inc Earnings CallMarch 15, 2024 | investorplace.comBFRI Stock Earnings: Biofrontera Beats EPS, Misses Revenue for Q4 2023February 28, 2024 | morningstar.comBiofrontera Inc BFRIFebruary 20, 2024 | marketwatch.comBiofrontera Up 56% After Revised Supply Agreement, Private Placement NewsFebruary 20, 2024 | msn.comWhat's Going On With Biofrontera Stock?April 23, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…February 6, 2024 | msn.comBiofrontera FDA Review Advances Ameluz® Dosage ExpansionFebruary 5, 2024 | finanznachrichten.deBiofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz to Permit Up to Three Tubes Per UseFebruary 5, 2024 | stockhouse.comBiofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluz(R) to Permit Up to Three Tubes Per UseFebruary 5, 2024 | finanznachrichten.dePTA-News: Biofrontera AG: Ameluz® erhält Zulassungserweiterung für Anwendung mit künstlichem Tageslicht in der EU und in GroßbritannienFebruary 3, 2024 | msn.comBiofrontera’s Pre-Funded Warrants Fully Exercised by InvestorFebruary 3, 2024 | msn.comBiofrontera Amends Agreement, Adjusts Payment ScheduleFebruary 2, 2024 | msn.comWhy Is Biofrontera (BFRI) Stock Down Today?January 26, 2024 | msn.comBiofrontera Receives Extension to Regain Nasdaq ComplianceJanuary 24, 2024 | finanznachrichten.dePTA-News: Biofrontera AG: EMA genehmigt optimierte Formulierung von Ameluz®January 11, 2024 | finanznachrichten.deBiofrontera Inc. Announces Preliminary Revenues for the Fourth Quarter and Full Year 2023January 9, 2024 | msn.comZulassung erweitert: Wie Biofrontera auf dem europäischen Markt durchstarten willJanuary 4, 2024 | marketwatch.comBiofrontera Shares Rise on Maruho SettlementNovember 16, 2023 | morningstar.comBiofrontera AG B8FAugust 31, 2023 | finanznachrichten.dePTA-News: Biofrontera AG: BIOFRONTERA BERICHTET ÜBER DIE ERGEBNISSE DES ERSTEN HALBJAHRES 2023August 29, 2023 | finance.yahoo.comBiofrontera Inc. Appoints Samantha Widdicombe to Support Commercial Relationships with Strategic Customer AccountsAugust 11, 2023 | msn.comBiofrontera Inc. (BFRI) Reports Q2 Loss, Lags Revenue EstimatesAugust 11, 2023 | finance.yahoo.comBiofrontera Inc. Reports Second Quarter 2023 Financial Results and Provides a Business UpdateAugust 10, 2023 | finanznachrichten.deBiofrontera Inc. Announces Last Patient Enrolled in Phase 3 Clinical Study Evaluating Ameluz-PDT for the Treatment of Basal Cell CarcinomaSee More Headlines Receive BFRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/24/2021Today4/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:BFRA CUSIPN/A CIK1712641 Webwww.biofrontera.com Phone(921) 487-6320Fax49-02-1487-6320Employees138Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,880,000.00 Net Margins-59.44% Pretax MarginN/A Return on Equity-93.31% Return on Assets-24.02% Debt Debt-to-Equity Ratio0.13 Current Ratio1.26 Quick Ratio1.13 Sales & Book Value Annual Sales$36.19 million Price / Sales2.04 Cash FlowN/A Price / Cash FlowN/A Book Value$0.35 per share Price / Book7.43Miscellaneous Outstanding Shares28,359,000Free FloatN/AMarket Cap$73.73 million OptionableNot Optionable Beta1.02 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesLudwig LutterChief Financial OfficerPamela KeckInvestor Relations ContactKey CompetitorsMediciNovaNASDAQ:MNOVTempest TherapeuticsNASDAQ:TPSTCue BiopharmaNASDAQ:CUECorvus PharmaceuticalsNASDAQ:CRVSAssertioNASDAQ:ASRTView All Competitors BFRA Stock Analysis - Frequently Asked Questions How were Biofrontera's earnings last quarter? Biofrontera AG (NASDAQ:BFRA) announced its quarterly earnings results on Wednesday, November, 24th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.03. The business earned $6.34 million during the quarter. Biofrontera had a negative net margin of 59.44% and a negative trailing twelve-month return on equity of 93.31%. What other stocks do shareholders of Biofrontera own? Based on aggregate information from My MarketBeat watchlists, some companies that other Biofrontera investors own include AbbVie (ABBV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Adaptimmune Therapeutics (ADAP), GW Pharmaceuticals (GWPH), Pfizer (PFE), Alnylam Pharmaceuticals (ALNY) and Ascendis Pharma A/S (ASND). When did Biofrontera IPO? Biofrontera (BFRA) raised $18 million in an initial public offering (IPO) on Wednesday, February 14th 2018. The company issued 1,500,000 shares at a price of $11.00-$13.00 per share. Benchmark served as the underwriter for the IPO and Dawson James Securities and Lake Street Capital Markets were co-managers. This page (NASDAQ:BFRA) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
